199 related articles for article (PubMed ID: 22693962)
1. Risk factors for liver transplant waitlist dropout in patients with hepatocellular carcinoma.
Park SJ; Freise CE; Hirose R; Kerlan RK; Yao FY; Roberts JP; Vagefi PA
Clin Transplant; 2012; 26(4):E359-64. PubMed ID: 22693962
[TBL] [Abstract][Full Text] [Related]
2. A new priority policy for patients with hepatocellular carcinoma awaiting liver transplantation within the model for end-stage liver disease system.
Piscaglia F; Camaggi V; Ravaioli M; Grazi GL; Zanello M; Leoni S; Ballardini G; Cavrini G; Pinna AD; Bolondi L
Liver Transpl; 2007 Jun; 13(6):857-66. PubMed ID: 17539006
[TBL] [Abstract][Full Text] [Related]
3. Validation of the HCC-MELD for dropout probability in patients with small hepatocellular carcinoma undergoing locoregional therapy.
Huo TI; Huang YH; Su CW; Lin HC; Chiang JH; Chiou YY; Huo SC; Lee PC; Lee SD
Clin Transplant; 2008; 22(4):469-75. PubMed ID: 18318736
[TBL] [Abstract][Full Text] [Related]
4. A follow-up analysis of the pattern and predictors of dropout from the waiting list for liver transplantation in patients with hepatocellular carcinoma: implications for the current organ allocation policy.
Yao FY; Bass NM; Nikolai B; Merriman R; Davern TJ; Kerlan R; Ascher NL; Roberts JP
Liver Transpl; 2003 Jul; 9(7):684-92. PubMed ID: 12827553
[TBL] [Abstract][Full Text] [Related]
5. Determination of the optimal model for end-stage liver disease score in patients with small hepatocellular carcinoma undergoing loco-regional therapy.
Huo TI; Wu JC; Lin HC; Lee FY; Hou MC; Huang YH; Lee PC; Chang FY; Lee SD
Liver Transpl; 2004 Dec; 10(12):1507-13. PubMed ID: 15558587
[TBL] [Abstract][Full Text] [Related]
6. Priority of candidates with hepatocellular carcinoma awaiting liver transplantation can be reduced after successful bridge therapy.
Cucchetti A; Cescon M; Bigonzi E; Piscaglia F; Golfieri R; Ercolani G; Cristina Morelli M; Ravaioli M; Daniele Pinna A
Liver Transpl; 2011 Nov; 17(11):1344-54. PubMed ID: 21837731
[TBL] [Abstract][Full Text] [Related]
7. Liver transplantation for hepatocellular carcinoma: analysis of survival according to the intention-to-treat principle and dropout from the waiting list.
Yao FY; Bass NM; Nikolai B; Davern TJ; Kerlan R; Wu V; Ascher NL; Roberts JP
Liver Transpl; 2002 Oct; 8(10):873-83. PubMed ID: 12360427
[TBL] [Abstract][Full Text] [Related]
8. MELDEQ : An alternative Model for End-Stage Liver Disease score for patients with hepatocellular carcinoma.
Marvin MR; Ferguson N; Cannon RM; Jones CM; Brock GN
Liver Transpl; 2015 May; 21(5):612-22. PubMed ID: 25694099
[TBL] [Abstract][Full Text] [Related]
9. Liver transplantation for hepatocellular carcinoma: lessons from the first year under the Model of End-Stage Liver Disease (MELD) organ allocation policy.
Yao FY; Bass NM; Ascher NL; Roberts JP
Liver Transpl; 2004 May; 10(5):621-30. PubMed ID: 15108253
[TBL] [Abstract][Full Text] [Related]
10. Effect of Mandatory 6-Month Waiting Period on Waitlist and Transplant Outcomes in Patients With Hepatocellular Carcinoma.
Nagai S; Kitajima T; Yeddula S; Salgia R; Schilke R; Abouljoud MS; Moonka D
Hepatology; 2020 Dec; 72(6):2051-2062. PubMed ID: 32157711
[TBL] [Abstract][Full Text] [Related]
11. Non-resective ablation therapy for hepatocellular carcinoma: effectiveness measured by intention-to-treat and dropout from liver transplant waiting list.
Fisher RA; Maluf D; Cotterell AH; Stravitz T; Wolfe L; Luketic V; Sterling R; Shiffman M; Posner M
Clin Transplant; 2004 Oct; 18(5):502-12. PubMed ID: 15344951
[TBL] [Abstract][Full Text] [Related]
12. The best candidates for transarterial chemotherapy in patients with hepatocellular carcinoma awaiting liver transplantation: a cohort-based characterization of dropout times.
Jang JW; Choi JY; Bae SH; Kim CW; Cho SH; Yoon SK; Yang JM; Han JY; Lee YS; Kim DG
Aliment Pharmacol Ther; 2007 Jul; 26(1):87-94. PubMed ID: 17555425
[TBL] [Abstract][Full Text] [Related]
13. Predictors of low risk for dropout from the liver transplant waiting list for hepatocellular carcinoma in long wait time regions: Implications for organ allocation.
Mehta N; Dodge JL; Hirose R; Roberts JP; Yao FY
Am J Transplant; 2019 Aug; 19(8):2210-2218. PubMed ID: 30861298
[TBL] [Abstract][Full Text] [Related]
14. A model for dropout assessment of candidates with or without hepatocellular carcinoma on a common liver transplant waiting list.
Toso C; Dupuis-Lozeron E; Majno P; Berney T; Kneteman NM; Perneger T; Morel P; Mentha G; Combescure C
Hepatology; 2012 Jul; 56(1):149-56. PubMed ID: 22271250
[TBL] [Abstract][Full Text] [Related]
15. Ablation therapy in containing extension of hepatocellular carcinoma: a simulative analysis of dropout from the waiting list for liver transplantation.
Yamashiki N; Tateishi R; Yoshida H; Shiina S; Teratani T; Sato S; Mine N; Kondo Y; Kawabe T; Omata M
Liver Transpl; 2005 May; 11(5):508-14. PubMed ID: 15838878
[TBL] [Abstract][Full Text] [Related]
16. Role of Locoregional Therapy and Predictors for Dropout in Patients with Hepatocellular Carcinoma Listed for Liver Transplantation.
Sheth RA; Patel MS; Koottappillil B; Shah JA; Oklu R; Mueller P; Vagefi PA; Ganguli S
J Vasc Interv Radiol; 2015 Dec; 26(12):1761-8; quiz 1768. PubMed ID: 26419427
[TBL] [Abstract][Full Text] [Related]
17. Drop-out rates of patients with hepatocellular cancer listed for liver transplantation: outcome with chemoembolization.
Maddala YK; Stadheim L; Andrews JC; Burgart LJ; Rosen CB; Kremers WK; Gores G
Liver Transpl; 2004 Mar; 10(3):449-55. PubMed ID: 15004776
[TBL] [Abstract][Full Text] [Related]
18. Liver transplantation for hepatocellular carcinoma: impact of the MELD allocation system and predictors of survival.
Ioannou GN; Perkins JD; Carithers RL
Gastroenterology; 2008 May; 134(5):1342-51. PubMed ID: 18471511
[TBL] [Abstract][Full Text] [Related]
19. Chemoembolization followed by liver transplantation for hepatocellular carcinoma impedes tumor progression while on the waiting list and leads to excellent outcome.
Graziadei IW; Sandmueller H; Waldenberger P; Koenigsrainer A; Nachbaur K; Jaschke W; Margreiter R; Vogel W
Liver Transpl; 2003 Jun; 9(6):557-63. PubMed ID: 12783395
[TBL] [Abstract][Full Text] [Related]
20. Direct-acting antivirals do not increase the risk of hepatocellular carcinoma recurrence after local-regional therapy or liver transplant waitlist dropout.
Huang AC; Mehta N; Dodge JL; Yao FY; Terrault NA
Hepatology; 2018 Aug; 68(2):449-461. PubMed ID: 29476694
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
